Literature DB >> 1254382

The human biotransformation of nalidixic acid.

H Graber, T Perényi, E Ludwig, M Arr.   

Abstract

Authors have developed new chemical methods for studying the human metabolism of nalidixic acid. The methods are suited for the quantitative determination of nalidixic acid, hydroxynalidixic acid, nalidixic acid glucuronide, hydroxynalidixic acid-glucuronide, and of free and total glucuronic acid excretion. The total urinary excretion of NA and its metabolites was found to be 50 to 100% of the ingested dose. The percentual distribution of the individual metabolites was as follows: NA 0,5-5, HNA2,5-6, NAG24-80, and HNAG11-26%. It was unanimously proved by enzymatic decomposition and specific chemical reactions that the excreted conjugates were monoglucuronides. The significance of individual differences, bilirubin metabolism, urinary pH and the pharmacokinetical behaviour of the individual metabolites is discussed from the therapeutic view.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1254382

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Biopharm        ISSN: 0340-0026


  4 in total

1.  Single- and multiple-dose pharmacokinetics of pipemidic acid in normal human volunteers.

Authors:  E Klinge; P T Männistö; R Mäntylä; J Mattila; U Hänninen
Journal:  Antimicrob Agents Chemother       Date:  1984-07       Impact factor: 5.191

2.  [Biotransformation of selected gyrase inhibitors].

Authors:  K Borner; H Lode
Journal:  Infection       Date:  1986       Impact factor: 3.553

3.  Probenecid inhibits the renal clearance and renal glucuronidation of nalidixic acid. A pilot experiment.

Authors:  T B Vree; M Van den Biggelaar-Martea; E W Van Ewijk-Beneken Kolmer; Y A Hekster
Journal:  Pharm World Sci       Date:  1993-08-20

4.  Direct gradient reversed-phase HPLC analysis and preliminary pharmacokinetics of nalidixic acid, 7-hydroxymethylnalidixic acid, 7-carboxynalidixic acid, and their corresponding glucuronide conjugates in humans.

Authors:  T B Vree; M van den Biggelaar-Martea; E W van Ewijk-Beneken Kolmer; Y A Hekster
Journal:  Pharm World Sci       Date:  1993-06-18
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.